P092: Estimating the dosimetric benefit of involved-node radiotherapy in comparison to involved-field radiotherapy - implications from the GHSG HD 17 trial

por Oertel, Michael, Hering, Dominik, Nacke, Nina, Kittel, Christopher, Kröger, Kai, Kriz, Jan, Fuchs, Michael, Baues, Christian, Vordermark, Dirk, Engenhart-Cabillic, Rita, Herfarth, Klaus, Lukas, Peter, Schmidberger, Heinz, Marnitz, Simone, Borchmann, Peter, Engert, Andreas, Haverkamp, Uwe, Eich, Hans Theodor
Publicado 2022

P093: From involved- field to involved-node – Quality analysis of the radiation therapy in HD 17 by the expert panel of the German Hodgkin Study Group

por Oertel, Michael, Hering, Dominik, Nacke, Nina, Kittel, Christopher, Kröger, Kai, Kriz, Jan, Fuchs, Michael, Baues, Christian, Vordermark, Dirk, Engenhart-Cabillic, Rita, Herfarth, Klaus, Lukas, Peter, Schmidberger, Heinz, Marnitz, Simone, Borchmann, Peter, Engert, Andreas, Haverkamp, Uwe, Eich, Hans Theodor
Publicado 2022

P097: The status quo of involved-field radiotherapy – Quality analysis of radiotherapy in the GHSG HD 16

por Oertel, Michael, Hering, Dominik, Kittel, Christopher, Nacke, Nina, Kröger, Kai, Kriz, Jan, Fuchs, Michael, Baues, Christian, Vordermark, Dirk, Engenhart-Cabillic, Rita, Herfarth, Klaus, Lukas, Peter, Schmidberger, Heinz, Marnitz, Simone, Borchmann, Peter, Haverkamp, Uwe, Engert, Andreas, Eich, Hans Theodor
Publicado 2022

Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern Era

por Oertel, Michael, Hering, Dominik, Nacke, Nina, Kittel, Christopher, Kröger, Kai, Kriz, Jan, Fuchs, Michael, Baues, Christian, Vordermark, Dirk, Engenhart-Cabillic, Rita, Herfarth, Klaus, Lukas, Peter, Schmidberger, Heinz, Marnitz, Simone, Borchmann, Peter, Engert, Andreas, Haverkamp, Uwe, Eich, Hans Theodor
Publicado 2022